



University of Dundee

Systemic potency of fluticasone in asthma

Lipworth, Brian; Kuo, Chris; Chan, Rory

Published in:
European Respiratory Journal

DOI:
[10.1183/13993003.00104-2020](https://doi.org/10.1183/13993003.00104-2020)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Lipworth, B., Kuo, C., & Chan, R. (2020). Systemic potency of fluticasone in asthma. *European Respiratory Journal*, 55(3), Article 2000104. <https://doi.org/10.1183/13993003.00104-2020>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Title: Systemic potency of fluticasone in asthma

Authors: Dr Brian Lipworth MD
Dr Chris RuiWen Kuo MBChB
Dr Rory Chan MBChB

Affiliation: Scottish Centre for Respiratory Research
University of Dundee
Ninewells Hospital and Medical School
Dundee, DD1 9SY
Scotland, UK

Corresponding author: Dr Brian Lipworth
Scottish Centre for Respiratory Research
University of Dundee
Ninewells Hospital and Medical School
Dundee, DD1 9SY
Scotland, UK
b.j.lipworth@dundee.ac.uk

Word count: 259

We read with interest the data from Maijers et al [1] suggesting that in a post hoc analysis of trials in oral corticosteroid (OC) dependent asthma, the majority of the OC sparing effects of high-dose inhaled corticosteroids are due to their systemic effects. The meta-regression estimates showed a prednisone (Pred) decrease of 4.9mg per 1.0mg increase in fluticasone propionate (FP) dose. This was based on the premise from an analysis of two studies where 1.0mg FP was equivalent to 5.0mg Pred for cortisol suppression, although this was only calculated in reference to a 10mg dose of Pred. A ratio of 1.02 was then inferred for the proportion of the OC sparing effect due to systemic absorption of FP.

In a prospective randomized controlled dose response comparison of placebo, Pred (5mg, 10mg, 20mg/day) and FP (0.44, 0.88, 1.76mg/day ex actuator) we calculated a relative dose potency for cortisol suppression of 8.5:1.0mg comparing Pred vs FP in adult asthma patients.[2] In turn the calculated systemic absorption ratio for FP would be 1.73 for OC sparing. Assuming part of the OC sparing effect of FP is due to suppression of type 2 inflammation, in the same dose response study the relative dose potency for blood eosinophil suppression was 5.3:1.0mg which would result in a systemic absorption ratio of 1.08 for FP.[2] In a meta-analysis of 21 studies the relative dose related cortisol suppression was 4.3 fold greater for FP than budesonide.[3] We would therefore concur with Maijers et al that use of high dose FP requires similar considerations as starting maintenance low-dose Pred.

References

1. Maijers I, Kearns N, Harper J, Weatherall M, Beasley R. Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma. *Eur Respir J* 2020: 55(1).
2. Wilson AM, Lipworth BJ. Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. *Br J Clin Pharmacol* 1999; 48(4): 579-585.
3. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. *Arch Intern Med* 1999; 159(9): 941-955.